208 related articles for article (PubMed ID: 35311126)
1. Real-World First-Line Treatment Patterns and Outcomes in Hormone Receptor-Positive Advanced Breast Cancer Patients: A Multicenter, Retrospective Study in China.
Chen Z; Ouyang Q; Wang Y; Wang J; Wang H; Wu X; Zhang P; Huang J; Zheng Y; Cao W; Shao X; Xie N; Tian C; Liang H; Wang C; Zhang Y; Ren D; Wang X
Front Oncol; 2022; 12():829693. PubMed ID: 35311126
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of palbociclib plus endocrine therapy for patients with HR
Zhong B; Zhang J; Wu J; Sun L; Li S; Zeng X; Gan L
Ann Transl Med; 2022 Mar; 10(6):362. PubMed ID: 35434007
[TBL] [Abstract][Full Text] [Related]
3. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
Tripathy D; Kaufman PA; Brufsky AM; Mayer M; Yood MU; Yoo B; Quah C; Yardley D; Rugo HS
Oncologist; 2013; 18(5):501-10. PubMed ID: 23652380
[TBL] [Abstract][Full Text] [Related]
4. Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.
Kotsakis A; Ardavanis A; Koumakis G; Samantas E; Psyrri A; Papadimitriou C
BMC Cancer; 2019 Jan; 19(1):88. PubMed ID: 30658600
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR
Shao B; Li H; Zhang J; Liu X; Song G; Jiang H; Yan Y; Wang H; Wang J; Di L
Ann Transl Med; 2022 Aug; 10(16):901. PubMed ID: 36111005
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer.
Yuan Y; Zhang S; Wang T; Bian L; Yan M; Yin Y; Song Y; Wen Y; Li J; Jiang Z
Chin Med J (Engl); 2023 Jun; 136(12):1459-1467. PubMed ID: 37101355
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China.
Lei W; Li H; Song G; Zhang R; Ran R; Yan Y; Di L; Jiang H
J Cancer; 2020; 11(22):6612-6622. PubMed ID: 33046982
[No Abstract] [Full Text] [Related]
8. Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes.
Carausu M; Carton M; Diéras V; Petit T; Guiu S; Gonçalves A; Augereau P; Ferrero JM; Levy C; Ung M; Desmoulins I; Debled M; Bachelot T; Pistilli B; Frenel JS; Mailliez A; Chevrot M; Cabel L
JAMA Netw Open; 2022 Dec; 5(12):e2247154. PubMed ID: 36520434
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of tucidinostat in patients with advanced hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: real-world insights.
Suo J; Zhu K; Zhuang C; Zhong X; Bravaccini S; Maltoni R; Bertucci F; Zheng H; Luo T
Ann Transl Med; 2023 Dec; 11(12):409. PubMed ID: 38213803
[TBL] [Abstract][Full Text] [Related]
11. CDK4/6 Inhibitors in Advanced HR+/HER2 - Breast Cancer: A Multicenter Real-World Data Analysis.
Müller C; Kiver V; Solomayer EF; Wagenpfeil G; Neeb C; Blohmer JU; Abramian AV; Maass N; Schütz F; Kolberg-Liedtke C; Ralser DJ; Rambow AC
Breast Care (Basel); 2023 Feb; 18(1):31-41. PubMed ID: 36876172
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA.
Lin PL; Hao Y; Xie J; Li N; Ohashi E; Koo V; Wu EQ
Expert Opin Pharmacother; 2015; 16(14):2101-11. PubMed ID: 26290278
[TBL] [Abstract][Full Text] [Related]
13. Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer.
Corbaux P; Lardy-Cleaud A; Alexandre M; Fontanilles M; Lévy C; Viansone AA; Mailliez A; Debled M; Goncalves A; Le Du F; Lerebours F; Ferrero JM; Eymard JC; Mouret-Reynier MA; Petit T; Frenel JS; Dalenc F; Courtinard C; Chaix M; Bachelot T
Breast Cancer Res Treat; 2022 Jan; 191(1):191-207. PubMed ID: 34687411
[TBL] [Abstract][Full Text] [Related]
14. Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China.
Wu Y; Han Y; Yu P; Ouyang Q; Yan M; Wang X; Hu X; Jiang Z; Huang T; Tong Z; Wang S; Yin Y; Li H; Yang R; Yang H; Teng Y; Sun T; Cai L; Li H; Chen X; He J; Liu X; Yang S; Qiao Y; Fan J; Wang J; Xu B
Front Oncol; 2020; 10():599604. PubMed ID: 33643905
[TBL] [Abstract][Full Text] [Related]
15. Survival outcomes of beta-blocker usage in HER2-positive advanced breast cancer patients: a retrospective cohort study.
Hsieh HH; Wu TY; Chen CH; Kuo YH; Hour MJ
Ther Adv Drug Saf; 2023; 14():20420986231181338. PubMed ID: 37359444
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors.
Zattarin E; Mariani L; Menichetti A; Leporati R; Provenzano L; Ligorio F; Fucà G; Lobefaro R; Lalli L; Vingiani A; Nichetti F; Griguolo G; Sirico M; Bernocchi O; Marra A; Corti C; Zagami P; Agostinetto E; Jacobs F; Di Mauro P; Presti D; Sposetti C; Giorgi CA; Guarneri V; Pedersini R; Losurdo A; Generali D; Curigliano G; Pruneri G; de Braud F; Dieci MV; Vernieri C
Ther Adv Med Oncol; 2023; 15():17588359231204857. PubMed ID: 38130467
[TBL] [Abstract][Full Text] [Related]
17. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study.
Yuan Y; Zhang S; Yan M; Yin Y; Song Y; Jiang Z
Ann Transl Med; 2021 May; 9(10):831. PubMed ID: 34164465
[TBL] [Abstract][Full Text] [Related]
19. A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.
Gamucci T; Mentuccia L; Natoli C; Sperduti I; Cassano A; Michelotti A; Di Lauro L; Sergi D; Fabi A; Sarobba MG; Marchetti P; Barba M; Magnolfi E; Maugeri-Saccà M; Rossi E; Sini V; Grassadonia A; Pellegrini D; Astone A; Nisticò C; Angelini F; Vaccaro A; Pellegrino A; De Angelis C; Palleschi M; Moscetti L; Bertolini I; Buglioni S; Giordano A; Pizzuti L; Vici P
J Cell Physiol; 2017 Jun; 232(6):1571-1578. PubMed ID: 27861874
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics, treatment patterns, and outcomes in adult patients with germline
Obeid E; Parikh RC; Esterberg E; Arondekar B; Hitchens A; Arruda LS; Niyazov A; Whitaker K
Front Oncol; 2024; 14():1341665. PubMed ID: 38817906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
